The United States of America is one of the Vaccine Alliance’s original six donor countries and has supported Gavi through direct funding since 2001. The partnership reflects long-standing US global health priorities, including preventing and controlling the spread of disease, supporting country ownership of health programmes and investing in life-saving efforts. Through Gavi, US funding supports the provision of vaccines and immunisations in lower-income countries.
US funding for Gavi has grown significantly since its initial contribution of US$ 48 million in 2001, reaching US$ 300 million annually in recent years. At Gavi’s first pledging conference in 2011, the United States pledged US$ 450 million for 2012–2014, followed by US$ 1 billion for 2015–2018 and US$ 1.16 billion for 2020–2023. The US was the largest donor to the Gavi COVAX AMC, contributing US$ 4 billion for vaccine procurement and delivery, alongside hundreds of millions of donated vaccine doses through COVAX. In 2024, US funding reached US$ 300 million per annum for the first time.
For Gavi’s 6.0 strategy period, covering 2026–2030, the United States has provided US$ 300 million in FY2025 funding and US$ 300 million in FY2026 funding, for a total of US$ 600 million. This renewed commitment builds on more than two decades of partnership between the United States and Gavi to expand access to life-saving vaccines.
*Local currency
†Proceeds are the funds that Gavi receives from donor commitments, either through direct donor payments, funding raised in advance against future donor pledges through IFFIm, or AMC funds released by the World Bank.
Hover over the bar chart above to view the data
Direct Contributions (including Matching Fund)
Non-US$ contributions are converted to US$ as follows:
IFFIm Contributions
Non-US$ contributions are converted to US$ as follows: